Unique and overlapping mechanisms of valbenazine, deutetrabenazine, and vitamin E for tardive dyskinesia
Schizophrenia (Heidelb). 2025 Apr 23;11(1):69. doi: 10.1038/s41537-025-00618-w.ABSTRACTIn 2017, the Food and Drug Administration (FDA) approved valbenazine and deutetrabenazine, two vesicular monoamine transporter 2 (VMAT2) inhibitors,...